Mono Pharmacare Limited (NSE:MONOPHARMA)
8.95
0.00 (0.00%)
Sep 10, 2026, 3:19 PM IST
Mono Pharmacare Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,657 | 1,683 | 1,223 | 330.87 | 369.83 |
Other Revenue | 0.14 | 0.89 | 0.25 | 0.57 | 1.1 |
| 1,657 | 1,684 | 1,224 | 331.44 | 370.93 | |
Revenue Growth | -1.62% | 37.65% | 269.19% | -10.65% | 30.71% |
Cost of Revenue | 1,568 | 1,524 | 1,107 | 292.42 | 347.3 |
Gross Profit | 88.67 | 160.72 | 116.75 | 39.02 | 23.63 |
Selling, General & Admin | 37.58 | 45.96 | 40.66 | 10.34 | 7.44 |
Other Operating Expenses | 11 | 36.73 | 12.11 | 5.7 | 2.28 |
Operating Expenses | 49.72 | 83.97 | 53.91 | 16.55 | 10.8 |
Operating Income | 38.94 | 76.76 | 62.83 | 22.48 | 12.84 |
Interest Expense | -33.18 | -35.53 | -28.47 | -8.46 | -6.55 |
Interest & Investment Income | - | 8.13 | 0.26 | 0.03 | 0.09 |
Other Non Operating Income (Expenses) | -0 | -4.72 | -2.36 | -0.86 | -0.87 |
Pretax Income | 5.76 | 44.63 | 32.26 | 13.18 | 5.51 |
Income Tax Expense | 2.24 | 13.57 | 7.67 | 3.73 | 2 |
Earnings From Continuing Operations | 3.53 | 31.06 | 24.59 | 9.45 | 3.51 |
Minority Interest in Earnings | 0 | -0.16 | -0.17 | -0.02 | - |
Net Income | 3.53 | 30.9 | 24.42 | 9.44 | 3.51 |
Net Income to Common | 3.53 | 30.9 | 24.42 | 9.44 | 3.51 |
Net Income Growth | -88.58% | 26.52% | 158.84% | 168.91% | 268.98% |
Shares Outstanding (Basic) | 18 | 18 | 15 | 6 | 5 |
Shares Outstanding (Diluted) | 18 | 18 | 15 | 6 | 5 |
Shares Change | -0.16% | 15.09% | 171.01% | 15.18% | - |
EPS (Basic) | 0.20 | 1.75 | 1.59 | 1.67 | 0.71 |
EPS (Diluted) | 0.20 | 1.75 | 1.59 | 1.67 | 0.71 |
EPS Growth | -88.56% | 10.00% | -4.55% | 134.45% | 274.94% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 22.92 | -45.29 | -89.47 | -401.73 | 2.26 |
Free Cash Flow Per Share | 1.30 | -2.56 | -5.83 | -70.92 | 0.46 |
Gross Margin | 5.35% | 9.54% | 9.54% | 11.77% | 6.37% |
Operating Margin | 2.35% | 4.56% | 5.13% | 6.78% | 3.46% |
Profit Margin | 0.21% | 1.84% | 2.00% | 2.85% | 0.95% |
Free Cash Flow Margin | 1.38% | -2.69% | -7.31% | -121.21% | 0.61% |
EBITDA | 40.09 | 78.04 | 63.98 | 22.98 | 13.92 |
EBITDA Margin | 2.42% | 4.63% | 5.23% | 6.93% | 3.75% |
D&A For EBITDA | 1.14 | 1.29 | 1.15 | 0.51 | 1.08 |
EBIT | 38.94 | 76.76 | 62.83 | 22.48 | 12.84 |
EBIT Margin | 2.35% | 4.56% | 5.13% | 6.78% | 3.46% |
Effective Tax Rate | 38.79% | 30.41% | 23.78% | 28.27% | 36.30% |
Revenue as Reported | 1,657 | 1,693 | 1,224 | 331.48 | 371.03 |
Advertising Expenses | - | 6.49 | 4.31 | 1.21 | 0.32 |